SENIOR PLC (SNR) — Investment Research Note

Executive summary

Senior is a UK-listed FTSE 250 aerospace and industrial engineering group focused on fluid conveyance and thermal management, with two divisions (Aerospace ~59% / Flexonics ~41% of revenue) selling into civil aerospace, defence, land vehicles and power & energy end markets. Operating trajectory has turned decisively positive — H1 2026 adjusted operating margin reached 10.0% (+170 bps constant currency), adjusted PBT +38%, and ROCE +260 bps to 14.5%, with both divisions firing 2026-08 half-year. The single most important valuation point today is that Senior is a near-closed take-private: on 7 April 2026 Zeus UK Bidco (Tinicum / Blackstone) agreed a 300p/share recommended cash offer, approved by 99.7% of votes on 26 May 2026, with 10 of 12 regulatory approvals already obtained and completion expected by end-2026 2026-04-07 Rule 2.7; 2026-08 half-year.

Fair value estimate

• Fair value range: 295p – 300p per share (≈ £1,235m – £1,255m market cap).
• Methodology: Deal-driven. The 297.85p cash consideration plus 2.15p FY25 final dividend sets the ceiling; the small discount reflects residual deal-break risk from the two outstanding regulatory approvals and a 3–4 month timing drag. Standalone DCF/multiple is secondary but useful as a break scenario: pre-bid 6-month VWAP of 218.1p plus modest fundamental improvement since suggests a standalone fair value of ~230–260p (10–11x FY26 adj. PBT ≈ £75m).
• Current market cap £1,243.8m vs. implied acquisition market cap £1,275m fully-diluted — the gap is almost entirely the time value of waiting plus deal risk.
• Absolute upside/downside: +0.8% to the deal cap, ~–15% to standalone break-case. The 15.2x FY25 EBITDA / 22.0x FY25 adj. operating profit the Consortium is paying is a full industrial price.

Sector context

Industrials / Industrial Goods & Services — confirmed. Senior sits in the aerospace components and industrial engineering niche. Quality has materially improved under the current strategy: FY25 ROCE of 13.1% and H1 2026 margins at or above medium-term targets place it in line with or above typical aerospace-components peers. Listed comparables: Melrose/GKN Aerospace, Senior's old peer Meggitt (acquired by Parker), TransDigm (US, premium quality), Chemring on defence overlap, and Hexcel/Spirit AeroSystems on composites. The Consortium is combining Senior with AeroFlow Technologies (ex-Leggett & Platt Aerospace Products Group) to build a larger private aerospace-components platform.

Investment thesis (3 bullets)

• Deal arbitrage with high completion probability: 99.7% shareholder approval, 10 of 12 regulatory approvals granted, Alantra (17.2%) and directors (0.6%) irrevocably committed, and Blackstone/Tinicum balance sheets backing the cash. Spread to 300p from 297.5p is ~0.8% for ≤3 months — a modest but low-risk arb return 2026-08 half-year; 2026-04-07 Rule 2.7.
• Underlying business momentum provides a soft floor: Aerospace order intake book-to-bill 1.17, Flexonics 1.32, group margin at 10%, net debt/EBITDA 0.9x, and expectations upgraded twice in 2026 (April and July trading updates) 2026-07-08 post-close update; 2026-08 half-year. Should the deal unexpectedly break, Senior is a stronger standalone than it was pre-bid.
• Semi-cap equipment adjacency gives a thin AI-receiver thread: Adjacent markets (largely semiconductor equipment) are ~9% of group and the semi-cap market is forecast to grow 23% in 2026 driven by AI/cloud infrastructure demand 2026-08 half-year. Material enough to notice, too small to drive the thesis.

Key risks (3 bullets)

• Deal break risk from remaining regulatory approvals including UK NSIA, French foreign investment, and competition clearances in several jurisdictions; the Consortium can walk if conditions related to Blackstone acquiring an interest in AeroFlow aren't satisfied 2026-04-07 Rule 2.7, Appendix I. If the deal breaks, downside to standalone fair value could be 15–20%+.
• Going-concern material uncertainty flagged by auditors: KPMG explicitly draws attention to a material uncertainty tied to change-of-control clauses in existing facilities — technical and not operationally alarming, but a reminder that financing is partially contingent on deal mechanics 2026-08 half-year, KPMG review.
• Cyclical end markets with limited AI-driven revenue line: 59% aerospace (civil aerospace is cyclical and depends on OEM build rates at Airbus/Boeing which have had their own stumbles), 26% land vehicles (heavy-duty truck pre-buy ahead of EPA-27 is a one-off cycle peak), 15% power & energy. Not disclosed but inferred: material commodity, FX (USD) and OEM-concentration risk.

Operating leverage

Senior is a typical scaled industrial with meaningful but not extreme operating leverage. The fixed-cost base is substantial (central costs ~£22.9m p.a. that don't scale; manufacturing footprint across 19 sites in 10 countries with heavy PP&E — £181.5m at H1 2026). The H1 2026 data point is informative: constant-currency revenue +7%, adjusted operating profit +28% — a drop-through of roughly 4x on top-line growth. Aerospace margins expanded 270 bps on 13% revenue growth; Flexonics margins expanded 20 bps on flat revenue (showing restructuring benefit) 2026-08 half-year. At current scale, a 10–20% revenue beat would plausibly add ~50% to operating profit — meaningful, but far short of software-grade leverage. Capacity utilisation is improving but not reported as fully utilised; the Thailand facility and Spencer are growth levers but each is a single-digit % of group.

Value-trap signals

None identified in the traditional sense, because the stock is not cheap and not a value trap — it is a near-completed takeover trading at the offer price. The one amber signal is the KPMG going-concern uncertainty note tied to change-of-control clauses, which is procedural rather than fundamental.

Earnings vs. expectations

Senior's 2025–26 pattern has been one of consistent upgrades: January 2026 FY25 post-close update stated results "ahead of expectations" with H2 outperformance; April 2026 Q1 update stated full-year performance now "comfortably ahead" of prior expectations; July 2026 half-year post-close update again raised expectations; and H1 2026 results delivered adjusted PBT +38% 2026-01, 2026-04, 2026-07, 2026-08. In FY24, the pattern was weaker — Boeing 737 MAX disruption led to a mid-year caution, though FY delivered growth. Pattern: 2024 one caution, 2025 in line to beat, 2026 three consecutive upgrades — this is a company currently beating expectations, which is partly why the Consortium pre-empted further value creation.

Conviction

Conviction: 5 (very high) — on the fair-value call, not on upside. The 300p deal price is contractually fixed, the regulatory process is 83% complete, and shareholder approval is overwhelming. Even if the deal unexpectedly collapsed, we have a strong-performing underlying business with clear valuation anchors (pre-bid VWAPs, improving fundamentals). Factors anchoring conviction: (i) 99.7% shareholder vote, (ii) 10/12 regulatory approvals banked, (iii) H1 2026 numbers confirm Consortium's valuation. Factors limiting: (i) 2 remaining regulatory clearances could theoretically snag, (ii) going-concern material-uncertainty note from KPMG, though technical.